Post
Amplia reports AMP945 data in preclinical model of pancreatic cancer
Amplia Therapeutics has reported data demonstrating the efficacy of AMP945 in a preclinical model of pancreatic cancer when used along …
Abbisko reports updated results from TGCT Phase Ib study
Abbisko Therapeutics has reported updated results from a Phase Ib study of Pimicotinib (ABSK021) for the treatment of advanced tenosynovial …
AstraZeneca reports positive results from endometrial cancer therapy trial
AstraZeneca has reported positive high-level results from the DUO-E trial (GOG 3041/ENGOT-EN10) of Imfinzi (durvalumab) and platinum-based chemotherapy combination followed …
Harbour reports results from HCC combo therapy trial
Harbour BioMed has reported results from a Phase Ib clinical trial of porustobart (HBM4003) combined with toripalimab for the treatment …
I-Mab reports encouraging data from Phase Ib/II NSCLC combo therapy trial
I-Mab has reported encouraging data from the Phase Ib/II study evaluating uliledlimab combined with toripalimab (TUOYI) in patients with treatment-naïve …
eFFECTOR reports interim data updates from cancer combo expansion cohort
eFFECTOR Therapeutics has reported positive interim data updates from a Phase II expansion cohort of zotatifin along with fulvestrant and …
Zentalis reports positive data from Phase Ib trial of cancer combo therapy
Zentalis Pharmaceuticals has reported positive data from a Phase Ib trial evaluating its WEE1 inhibitor, azenosertib combined with chemotherapy in …
FDA greenlights Neuralink for human trials
The US Food and Drug Administration (FDA) has approved Neuralink for its first in-human study. In a Twitter announcement, the …
Pfizer’s etrasimod aims to differentiate UC market with strong safety profile
The market for ulcerative colitis (UC) is filled with various treatment options, and the pipeline is relatively strong. The variety …
Xilio reports preliminary data from Phase I solid tumours therapy trial
Xilio Therapeutics has reported preliminary data from its Phase I clinical trial of XTX101 for the treatment of advanced solid …
Oncolytics gears up for Phase III trial in HR+/HER2- breast cancer
Oncolytics Biotech is getting ready for a registrational Phase III clinical trial after announcing positive results from a Phase II …
Topas launches Phase IIa trial of celiac disease therapy
Topas Therapeutics has launched a Phase IIa clinical trial of TPM502 to treat patients with celiac disease, an autoimmune disorder. The …
Stallergenes Greer initiates Phase III study of Staloral Birch
Stallergenes Greer has initiated a Phase III clinical study of Staloral Birch to treat children and adolescents with birch pollen-induced …
BIAL R&D doses first patient in ACTIVATE study of BIA 28-6156
BIAL R&D has dosed the first patient in its Phase II ACTIVATE study of BIA 28-6156 to treat patients with …
Transgene and BioInvent report positive data for oncolytic virus
BioInvent International and Transgene’s partnership is looking optimistic following positive Phase 1a data on its oncolytic virus BT-001 for the …